Artikkelit

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient activity of the enzyme acid β glucosidase.

Understanding the psychological burden of switching insulin. Discover ways to cope and support patient well-being during treatment changes.

Learn why timely insulin transitions are critical for patient safety and continuity of care. Act early to avoid gaps and risks.

Gaucher disease is a lysosomal storage disorder caused by a pathogenic variant in the gene responsible for producing the enzyme acid β-glucosidase. More than 300 alleles carrying pathogenic variants have already been identified.¹

Autoimmune Type 1 Diabetes (T1D) can be detected through islet autoantibody testing years before symptoms appear.^1-2 The video here explains how the condition progresses silently through presymptomatic stages, with beta cell destruction occurring long before symptom onset and clinical diagnosis.^4-8

Parent's experiences of stage 3 diagnosis of T1D.